biostudies-literatureZhang BCMultiple Sclerosis Society105873https://www.ebi.ac.uk/biostudies/studies/S-EPMC12336691biostudies-literatureUnknown118<h4>Background</h4>Glatiramer acetate (GA) is a well-tolerated treatment for multiple sclerosis (MS) and comparable in its efficacy to high-dose interferon beta (IFN). As a lack of validated treatment response biomarkers for MS hampers progress in personalised treatment, the study goal was to search for biomarkers of a successful treatment response utilising the known observation of T-cell expansions after GA treatment.<h4>Methods</h4>T-cell receptor beta chain (TRB) sequencing was performed in 3021 patients with MS: a discovery cohort of 1627 patients with MS, 204 of whom had previously been treated with GA, and then validated in 1394 patients with MS, 424 of whom had previously been treated with GA. Clinical data from 1987 patients with MS treated with GA or IFN and available HLA informaEBioMedicineHLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis.PMC1233669110.1Schneider-Hohendorf THenry RGGisevius BKowarik MRevie LOksenberg JMendoza MRothhammer VCooper TPleasure SBucciarelli FDeffner MHarms MStern WAHeesen CBaranzini SGreen AJCaverzasi EGiede-Jeppe ACaillier SMeyer Zu Horste GKumpfel TGuo CYNischwitz SPaul FHollenbach JTrebst CSeidel CHavla JPapinutto NMeuth SGLiblau RFalk SGross CCGerman Competence Network Multiple Sclerosis (KKNMS)Schwab NThen Bergh FGerdes LAKerschensteiner MPignolet BUniversity of California San Francisco MS-EPIC TeamRobins HTumani HWiendl HSalmen ASantaniello AMay DGold RJarius SBittner SOksenberg JRAlexander JZamvil SKlotz LElyanow RZettl UAktas OCaillier SJFriese MARothacher SCree BACHauser SLCuneo RZhang BCAntony GSabatino JJGupta SLuessi FZipp FWilson MRDawin ESenel MKnop MZamvil SSSeipelt MBayas AHayashi FHenry RYusko EGomez RWunsch CWildemann BBove RMattox DGelfand JMfalseHLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis.<h4>Background</h4>Glatiramer acetate (GA) is a well-tolerated treatment for multiple sclerosis (MS) and comparable in its efficacy to high-dose interferon beta (IFN). As a lack of validated treatment response biomarkers for MS hampers progress in personalised treatment, the study goal was to search for biomarkers of a successful treatment response utilising the known observation of T-cell expansions after GA treatment.<h4>Methods</h4>T-cell receptor beta chain (TRB) sequencing was performed in 3021 patients with MS: a discovery cohort of 1627 patients with MS, 204 of whom had previously been treated with GA, and then validated in 1394 patients with MS, 424 of whom had previously been treated with GA. Clinical data from 1987 patients with MS treated with GA or IFN and available HLA informa2025-01-01T00:00:00Z2025 Aug2026-05-04T16:43:15.324Z2026-04-25T03:11:33.62ZS-EPMC123366914074952510.1016/j.ebiom.2025.105873